Drug toxicity

Researcher in a medical lab
#3D cell culture #3D modelling #ADME / Tox #Drug toxicity #Pharmokinetics #Webinar

Webinar: Create advanced predictive models for tox testing

Join DDW and Lonza for this free event ‘Building advanced cell models for toxicity testing’. The event will take place on 19 September at 3pm GMT / 4pm CET / 10am EST / 7am PST. Life sciences researchers need a host… Read More

Webinar date:
Supported by Lonza
#News

Scientist working in the lab
#3D cell culture #3D modelling #ADME / Tox #Drug toxicity #Pharmokinetics #Webinar

Webinar: Building advanced cell models for toxicity testing

Join DDW and Lonza for this free event ‘Building advanced cell models for toxicity testing’. The event will take place on 19 September at 3pm GMT / 4pm CET / 10am EST / 7am PST. Life sciences researchers need a host… Read More

Webinar date:
Supported by Lonza
#News

Scientist working in the lab
#3D cell culture #3D modelling #ADME / Tox #Drug toxicity #Pharmokinetics

Building advanced cell models for toxicity testing

Life sciences researchers need a host of tools to develop and test critical disease-treating drugs and therapies, from basic research to final product release. Primary cells, media, and reagents are all important for supporting preclinical and clinical pharmaceutical workflows for drug discovery and absorption, distribution, metabolism, excretion, and toxicity (ADMET)… Read More

Webinar date:
Supported by Lonza
#Webinars

A laboratory mouse
#Clinical trials #Drug toxicity #In vivo #Mouse models #Preclinical development #Whitepaper

How can you ensure a confident transition to human trials?

A new whitepaper is now available from The Jackson Laboratory, entitled ‘Evidence-based selection of the starting dose in first-in-human clinical trials using humanised mouse models‘. This paper discusses the challenges drug developers face when transitioning from preclinical discovery to clinical trials and proposes expanding the drug development… Read More

#News

#Clinical trials #Drug toxicity #In vivo #Mouse models #Preclinical development

The in vivo tool enabling a confident transition to Phase I trials

This paper discusses the challenges drug developers face when transitioning from preclinical discovery to clinical trials and proposes expanding the drug development toolbox with humanised mouse models. Download the latest whitepaper to learn more about: The importance of selecting appropriate starting doses in clinical trials. Why humanised mice better predict… Read More

#Resources

#ADME / Tox #Cellular assays #Drug toxicity #Market reporting #Omics #Toxicology

Late-stage drug failures drive toxicology testing market growth

The global ADME toxicology testing market is predicted to generate a revenue of $19.21 billion by 2030, with a growth rate of 10.2%. Factors such as an increased need to check late-stage drug failures with the adoption of more appropriate toxicity testing methods by pharmaceutical companies are expected to aid… Read More

#Business & Investment #News

Mouse in laboratory
#Clinical trials #Drug toxicity #Mouse models #Pharmacology #Preclinical investigations #Whitepaper

Whitepaper: Ensure accurate dose prediction for clinical trials

Accurate dose prediction for clinical trials is essential to ensure patient safety and trial success. This new whitepaper from the Jackson Laboratory discusses evidence-based selection of starting doses in first-in-human clinical trials through the utilisation of humanised mouse models. In this whitepaper you will learn about: The significance… Read More

#News

#Clinical trials #Drug toxicity #Mouse models #Pharmacology #Preclinical investigations

Discover evidence-based, first-in-human dose selection

This whitepaper discusses evidence-based selection of starting doses in first-in-human clinical trials through the utilisation of humanised mouse models and emphasises the importance of accurate dose prediction to ensure patient safety and trial success. In this whitepaper you will learn about: The significance of selecting appropriate starting doses in clinical… Read More

#Resources

Using C. elegans to screen compounds
#C elegans #Drug screening #Drug toxicity #Financing #Investment #Research services

Anti-ageing research company secures investment

Magnitude Biosciences has closed a fourth round of investment to accelerate the scaling of its business providing C. elegans research services.   A total investment of £500,000 will be made by longstanding investors the North East (ERDF) Innovation Fund Limited Partnership, supported by the European Regional Development Fund and managed by… Read More

#Business & Investment #News

#Assay development optimisation & technology #Assays #Drug discovery #Drug toxicity #In vitro #Podcast

Podcast: Paving the way for optimum drug discovery

This is the latest episode of the free DDW podcast, “Paving the way for optimum drug discovery”. It covers two narrated articles written for Volume 22, Issue 1 – Winter 2020/21 of DDW and they are read aloud by Megan Thomas. These articles are titled: “In vitro models for assessing… Read More

#News

#Drug efficacy #Drug safety #Drug toxicity #Preclinical investigations

How to enhance the predictability of preclinical development: webinar

Effective preclinical assessment of drug safety and efficacy is essential to help reduce the risk of drug-induced toxicity and late-stage drug attrition. Current preclinical tests for safety depend on in vivo testing in higher-order species to achieve translational accuracy; however, animal models are expensive and do not adequately recapitulate human… Read More

#Editor's Choice #News

#Assay #Drug development #Drug toxicity #Preclinical development #Toxicology

Enhancing the predictability of drug toxicity and efficacy

There is an unmet clinical need in drug development for in vitro models that reduce the risk of drug-induced toxicity and late-stage drug attrition. In this webinar, hosted on May 26 2021, two expert speakers discuss how researchers can enhance the predictability of pre-clinical drug development. This webinar, Enhancing the predictability of… Read More

#Editor's Choice #News

#Assays #Clinical trials #Drug toxicity #Preclinical development #Toxicology

Driving the success of predictability in preclinical development 

The development of predictive preclinical assays is key to success in drug development. It is therefore critical to carefully construct biomarker studies using the most appropriate assays that better represent the complex physiology of disease for the reliable assessment of safety, efficacy, and dose predictions. To explore this topic further, Dr. Hyelim Cho, Group Lead, Immunogenicity, Global DMPK Oncology and Rare Diseases,… Read More

#Editor's Choice #News

#Drug safety #Drug toxicity #Preclinical development

How to enhance the predictability of preclinical development: webinar

Effective preclinical assessment of drug safety and efficacy is essential to help reduce the risk of drug-induced toxicity and late-stage drug attrition. Current preclinical tests for safety depend on in vivo testing in higher-order species to achieve translational accuracy; however, animal models are expensive and do not adequately recapitulate human… Read More

#Editor's Choice #News